216 related articles for article (PubMed ID: 36797240)
1. Polo-like kinase 4 (Plk4) potentiates anoikis-resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotype.
Fonseca I; Horta C; Ribeiro AS; Sousa B; Marteil G; Bettencourt-Dias M; Paredes J
Cell Death Dis; 2023 Feb; 14(2):133. PubMed ID: 36797240
[TBL] [Abstract][Full Text] [Related]
2. Autophosphorylation-induced self-assembly and STIL-dependent reinforcement underlie Plk4's ring-to-dot localization conversion around a human centriole.
Park JE; Meng L; Ryu EK; Nagashima K; Baxa U; Bang JK; Lee KS
Cell Cycle; 2020 Dec; 19(24):3419-3436. PubMed ID: 33323015
[TBL] [Abstract][Full Text] [Related]
3. PLK4: a promising target for cancer therapy.
Zhao Y; Wang X
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2413-2422. PubMed ID: 31492983
[TBL] [Abstract][Full Text] [Related]
4. Plk4 trans-autophosphorylation regulates centriole number by controlling betaTrCP-mediated degradation.
Guderian G; Westendorf J; Uldschmid A; Nigg EA
J Cell Sci; 2010 Jul; 123(Pt 13):2163-9. PubMed ID: 20516151
[TBL] [Abstract][Full Text] [Related]
5. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4.
Mittal K; Kaur J; Sharma S; Sharma N; Wei G; Choudhary I; Imhansi-Jacob P; Maganti N; Pawar S; Rida P; Toss MS; Aleskandarany M; Janssen EA; Søiland H; Gupta MV; Reid MD; Rakha EA; Aneja R
Mol Cancer Res; 2022 Apr; 20(4):596-606. PubMed ID: 34933912
[TBL] [Abstract][Full Text] [Related]
7. Phase separation of Polo-like kinase 4 by autoactivation and clustering drives centriole biogenesis.
Park JE; Zhang L; Bang JK; Andresson T; DiMaio F; Lee KS
Nat Commun; 2019 Oct; 10(1):4959. PubMed ID: 31672968
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
Tordjman J; Majumder M; Amiri M; Hasan A; Hess D; Lala PK
BMC Cancer; 2019 Jun; 19(1):561. PubMed ID: 31185986
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer: A Mini Patent Review.
Shu Y; Liu Y; Bian S; Xie Z; Liao C
Mini Rev Med Chem; 2023; 23(1):67-79. PubMed ID: 35657046
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
Tian X; Zhou D; Chen L; Tian Y; Zhong B; Cao Y; Dong Q; Zhou M; Yan J; Wang Y; Qiu Y; Zhang L; Li Z; Wang H; Wang D; Ying G; Zhao Q
Cell Death Dis; 2018 Jan; 9(2):54. PubMed ID: 29352113
[TBL] [Abstract][Full Text] [Related]
11. PLK4: a link between centriole biogenesis and cancer.
Maniswami RR; Prashanth S; Karanth AV; Koushik S; Govindaraj H; Mullangi R; Rajagopal S; Jegatheesan SK
Expert Opin Ther Targets; 2018 Jan; 22(1):59-73. PubMed ID: 29171762
[TBL] [Abstract][Full Text] [Related]
12. Cep152 acts as a scaffold for recruitment of Plk4 and CPAP to the centrosome.
Cizmecioglu O; Arnold M; Bahtz R; Settele F; Ehret L; Haselmann-Weiss U; Antony C; Hoffmann I
J Cell Biol; 2010 Nov; 191(4):731-9. PubMed ID: 21059844
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 4 controls centriole duplication but does not directly regulate cytokinesis.
Holland AJ; Fachinetti D; Da Cruz S; Zhu Q; Vitre B; Lince-Faria M; Chen D; Parish N; Verma IM; Bettencourt-Dias M; Cleveland DW
Mol Biol Cell; 2012 May; 23(10):1838-45. PubMed ID: 22456511
[TBL] [Abstract][Full Text] [Related]
14. Functional relationship among PLK2, PLK4 and ROCK2 to induce centrosome amplification.
Ling H; Hanashiro K; Luong TH; Benavides L; Fukasawa K
Cell Cycle; 2015; 14(4):544-53. PubMed ID: 25590559
[TBL] [Abstract][Full Text] [Related]
15. Autoinhibition and relief mechanism for Polo-like kinase 4.
Klebba JE; Buster DW; McLamarrah TA; Rusan NM; Rogers GC
Proc Natl Acad Sci U S A; 2015 Feb; 112(7):E657-66. PubMed ID: 25646492
[TBL] [Abstract][Full Text] [Related]
16. The autoregulated instability of Polo-like kinase 4 limits centrosome duplication to once per cell cycle.
Holland AJ; Fachinetti D; Zhu Q; Bauer M; Verma IM; Nigg EA; Cleveland DW
Genes Dev; 2012 Dec; 26(24):2684-9. PubMed ID: 23249732
[TBL] [Abstract][Full Text] [Related]
17. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y
Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033
[TBL] [Abstract][Full Text] [Related]
18. Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma.
Jia J; Zhang W; Liu JY; Chen G; Liu H; Zhong HY; Liu B; Cai Y; Zhang JL; Zhao YF
PLoS One; 2012; 7(12):e51549. PubMed ID: 23272116
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability.
Holland AJ; Lan W; Niessen S; Hoover H; Cleveland DW
J Cell Biol; 2010 Jan; 188(2):191-8. PubMed ID: 20100909
[TBL] [Abstract][Full Text] [Related]
20. The HPV-16 E7 oncoprotein induces centriole multiplication through deregulation of Polo-like kinase 4 expression.
Korzeniewski N; Treat B; Duensing S
Mol Cancer; 2011 May; 10():61. PubMed ID: 21609466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
